Orchestra BioMed Reports Third Quarter 2026 Financial Results and Business Updates

Orchestra BioMed reported that it completed enrollment of 349 patients in the BACKBEAT Global Pivotal Trial of AVIM Therapy, with primary endpoint data expected at the Heart Rhythm Society meeting in 2027. The company said site activation and enrollment are accelerating in its Virtue Trial, which compares the Virtue SAB system with the AGENT paclitaxel-coated balloon. A public offering that closed November 9, 2026, generated approximately $80.5 million in net proceeds; combined with cash and marketable securities held at September 30, the funds are expected to support operations through 2028. The article did not provide quarterly revenue or profit figures or report a stock-price move.